secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASHLAND INC. (ASH)
CIK:        0001674862
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055047
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.06, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ashland to sell nutraceuticals business to Turnspire; expects $110-120M impairment in Q3 FY2024
--------------------------------------------------------------------------------

- Signed definitive agreement to sell nutraceuticals business to Turnspire Capital Partners; closing expected calendar Q3 2024.
- Expects non-cash impairment charge of $110M to $120M in Q3 fiscal 2024, substantially offset by tax benefits.
- Nutraceuticals business supplies active ingredients and formulation aids from four facilities in US and Mexico.
- No purchase price disclosed in the filing.
- Citi and Cravath, Swaine & Moore are acting as financial and legal advisors to Ashland.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674862/000095017024055047/0000950170-24-055047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674862/000095017024055047/ash-20240506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer